share_log

AbbVie | 8-K: AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense

AbbVie | 8-K: Current report

艾伯维公司 | 8-K：重大事件
SEC announcement ·  04/03 16:12
Moomoo AI 已提取核心信息
AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
AbbVie Inc., a biopharmaceutical company, has released preliminary financial results for the first quarter of 2024, including an update on its earnings guidance. The company expects to report acquired IPR&D and milestones expense of $164 million on a pre-tax basis, which will negatively impact both GAAP and non-GAAP diluted earnings per share by $0.08. These results are not yet finalized and are subject to financial statement closing procedures. AbbVie has updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, reflecting the impact of the first quarter expenses. The first quarter adjusted diluted earnings per share guidance is set between $2.18 and $2.22, inclusive of the acquired IPR&D and milestones expense. The company's guidance for the remainder of the year excludes any potential acquired IPR&D and milestones expense due to the unpredictable nature of such transactions. AbbVie's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.
生物制药公司艾伯维公司发布了2024年第一季度的初步财务业绩，包括最新的收益指引。该公司预计将在税前基础上报告收购的IPR&D和里程碑支出为1.64亿美元，这将对GAAP和非GAAP摊薄后的每股收益产生0.08美元的负面影响。这些结果尚未最终确定，需要遵守财务报表结算程序。艾伯维已将其2024年全年调整后的摊薄后每股收益指引更新至10.97美元至11.17美元之间，反映了第一季度支出的影响。第一季度调整后的摊薄后每股收益指引定在2.18美元至2.22美元之间，其中包括收购的IPR&D和里程碑支出。由于此类交易的不可预测性，该公司对今年剩余时间的指导不包括任何潜在收购的知识产权研发和里程碑费用。艾伯维的前瞻性陈述受风险和不确定性的影响，可能导致实际业绩与预期存在重大差异。
生物制药公司艾伯维公司发布了2024年第一季度的初步财务业绩，包括最新的收益指引。该公司预计将在税前基础上报告收购的IPR&D和里程碑支出为1.64亿美元，这将对GAAP和非GAAP摊薄后的每股收益产生0.08美元的负面影响。这些结果尚未最终确定，需要遵守财务报表结算程序。艾伯维已将其2024年全年调整后的摊薄后每股收益指引更新至10.97美元至11.17美元之间，反映了第一季度支出的影响。第一季度调整后的摊薄后每股收益指引定在2.18美元至2.22美元之间，其中包括收购的IPR&D和里程碑支出。由于此类交易的不可预测性，该公司对今年剩余时间的指导不包括任何潜在收购的知识产权研发和里程碑费用。艾伯维的前瞻性陈述受风险和不确定性的影响，可能导致实际业绩与预期存在重大差异。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息